{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004721","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.830383+00:00","generated_at":"2026-05-31T09:49:17.606259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance","bullets":["Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.","Cash $9.3M at Jun 30, up from $3.4M at Dec 31; cash used in ops $2.3M for Q2, reduced from $4.2M YoY.","Closed $5.8M PIPE at 25% premium to new investor; cash runway extended into 2025.","AgenT-797: Phase 2 gastric cancer advancing, early data at upcoming conference; Phase 1 GvHD activation planned; ARDS expanded access shows clinical benefit."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004721","json":"https://secwatch.observer/filing/0001171843-24-004721.json","markdown":"https://secwatch.observer/filing/0001171843-24-004721.md","text":"https://secwatch.observer/filing/0001171843-24-004721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324004721/0001171843-24-004721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324004721/f8k_081324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:49:17.606259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}